Research programme: dianexin - Athera Biotechnologies

Drug Profile

Research programme: dianexin - Athera Biotechnologies

Alternative Names: Annexin A5 - Athera Biotechnologies; Recombinant Annexin A5 - Athera Biotechnologies

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Athera Biotechnologies
  • Class Proteins
  • Mechanism of Action Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Acute coronary syndromes

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Acute coronary syndromes in Sweden
  • 21 Mar 2011 Dianexin is available for licensing as of 17 Mar 2011. http://www.athera.se/
  • 21 Jan 2009 Early research in Acute coronary syndromes in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top